Document 2439
 DOCN  M94A2439
 TI    Associated seroconversion to HIV-HBV.
 DT    9412
 AU    Roberto F; Raiteri R; Sciandra M; Sinicco A; Inst. of Infect. Diseases,
       Univ. of Turin, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):304 (abstract no. PC0146). Unique
       Identifier : AIDSLINE ICA10/94370136
 AB    OBJECTIVE: To assess the associated seroconversion to HIV-HBV (HIV-HBV
       SC) among i.v. drug users (IDUs). METHODS: From March 1986 to December
       1993, 120 out of 2368 IDUs periodically tested for HIV and HBV markers,
       with negative test for HIV within the previous 6 months had
       seroconversion to HIV (group A). As controls, 364 IDUs matched by sex,
       age and i.v. drug use characteristics, who remained negative to HIV at
       the end of the study, were employed (group B). RESULTS: Fourteen of 41
       participants negative to HBV markers had HBV infection in group A vs 20
       of 144 in group B (OR = 3.2; p = .006). On univariate analysis, HIV-HBV
       SC was related to drug debut after 1988 (OR = 6.5; CI = 1.21-34.5; p =
       .019), recent debut of drug use (OR = 5.3; CI = 1.2-23.7; p = .021),
       high frequency of drug injecting (OR = 8.7; CI = 1.9-39.8, p = .003),
       alcohol abuse (OR = 1.33; CI = 0.19-9.1; p = .000), high number of
       sexual partners (OR = 3.8; CI = 0.97-14.9; p = .000) and history of STDs
       (OR = 4.33; CI = 0.36-52.6; p = .000). On multivariate analysis, only
       high frequency of i.v. drug injecting remained independently linked to
       HIV-HBV SC (beta = 2.72; OR = 15.2; p = .01). CONCLUSIONS: Counseling
       and early vaccinal program to HBV are to be tailored primarily to IDUs
       who start injecting and are susceptible to HBV because of the influence
       that HIV and HBV may have on each other.
 DE    Hepatitis B/PREVENTION & CONTROL/TRANSMISSION  Hepatitis B
       Antibodies/*ANALYSIS  Human  HIV Infections/TRANSMISSION  *HIV
       Seropositivity  Risk Factors  Substance Abuse,
       Intravenous/*COMPLICATIONS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).